Last reviewed · How we verify
FLOX
FLOX is a Small molecule drug developed by Hospira. It is currently FDA-approved for Malignant neoplasm of liver, Primary malignant neoplasm of gastrointestinal tract. Also known as: Oxaliplatin, 5-fluorouracil, Leucovorin.
Flox, marketed by Hospira, is a therapeutic agent indicated for malignant neoplasm of the liver. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk lies in the lack of reported key trial results and revenue data, which may affect investor confidence and market positioning.
At a glance
| Generic name | FLOX |
|---|---|
| Also known as | Oxaliplatin, 5-fluorouracil, Leucovorin |
| Sponsor | Hospira |
| Target | Thymidylate synthase, Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant neoplasm of liver
- Primary malignant neoplasm of gastrointestinal tract
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Enteritis
- Stomatitis
- Localized erythema
- Anemia
- Leukopenia
- Thrombocytopenia
- Elevated alkaline phosphatase
- Elevated serum transaminase
- Elevated serum bilirubin
Serious adverse events
- Arterial thrombosis
- Arterial aneurysm
- Arterial ischemia
- Hepatic necrosis
- Myocardial ischemia
- Embolism
- Thrombophlebitis
- Duodenal ulcer
- Acalculous cholecystitis
- Anaphylaxis
Key clinical trials
- METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (PHASE2)
- METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (PHASE2)
- Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer
- Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
- Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime (NA)
- Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer (PHASE1,PHASE2)
- Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy (PHASE3)
- FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLOX CI brief — competitive landscape report
- FLOX updates RSS · CI watch RSS
- Hospira portfolio CI
Frequently asked questions about FLOX
What is FLOX?
What is FLOX used for?
Who makes FLOX?
Is FLOX also known as anything else?
What development phase is FLOX in?
What are the side effects of FLOX?
What does FLOX target?
Related
- Target: All drugs targeting Thymidylate synthase, Thymidylate synthase
- Manufacturer: Hospira — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Malignant neoplasm of liver
- Indication: Drugs for Primary malignant neoplasm of gastrointestinal tract
- Also known as: Oxaliplatin, 5-fluorouracil, Leucovorin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing